Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo.
about
Respiratory viruses other than influenza virus: impact and therapeutic advancesHuman Metapneumovirus: lessons learned over the first decadePhylogenetic and phylodynamic analyses of human metapneumovirus in Buenos Aires (Argentina) for a three-year period (2009-2011)Cell Type-Specific Recognition of Human Metapneumoviruses (HMPVs) by Retinoic Acid-Inducible Gene I (RIG-I) and TLR7 and Viral Interference of RIG-I Ligand Recognition by HMPV-B1 PhosphoproteinStructure of the human metapneumovirus fusion protein with neutralizing antibody identifies a pneumovirus antigenic siteHuman metapneumovirus in adultsIdentification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening.A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo.Human metapneumovirus virus-like particles induce protective B and T cell responses in a mouse model.Interferon γ-inducible protein (IFI) 16 transcriptionally regulates type i interferons and other interferon-stimulated genes and controls the interferon response to both DNA and RNA virusesThe characterization of monoclonal antibodies to human metapneumovirus and the detection of multiple forms of the virus nucleoprotein and phosphoprotein.A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus.Lung CD8+ T Cell Impairment Occurs during Human Metapneumovirus Infection despite Virus-Like Particle Induction of Functional CD8+ T Cells.A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSVThe human metapneumovirus fusion protein mediates entry via an interaction with RGD-binding integrins.Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirusHuman metapneumovirus reinfection among children in Thailand determined by ELISA using purified soluble fusion protein.Human metapneumovirus in the preterm neonate: current perspectivesNew Approaches for Immunization and Therapy against Human MetapneumovirusHuman metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review.Antiviral therapy for respiratory viral infections in immunocompromised patients.A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirusSerious outbreak of human metapneumovirus in patients with hematologic malignancies.Biochemical, conformational, and immunogenic analysis of soluble trimeric forms of henipavirus fusion glycoproteins.Cross-neutralization of four paramyxoviruses by a human monoclonal antibody.Genetic diversity and evolution of human metapneumovirus fusion protein over twenty yearsStructure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein.Human antibody recognition of antigenic site IV on Pneumovirus fusion proteins.Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer
P2860
Q24655957-27728DB4-460B-4ABD-AA2A-40EF25BDC3B3Q26822938-5A92A7AA-91E7-4CA9-9375-DD0FABF1B3F4Q27321317-5CDDD982-F25E-4BE5-BE41-64F5C907CA48Q27491027-AD3BCB8B-6C5F-4585-B628-3CDF22F484D9Q27677823-6263188A-46E7-4FA0-8F87-09C96F6756CFQ27694039-0A3B24BC-139C-4385-AC89-26763FBB1514Q30423024-E3B6043F-7C8E-4DF7-95B9-6BD0EE28E83AQ33285591-8D7B9788-F601-4DA6-A466-4FE576A7D697Q33887642-6672390A-C77A-4C4C-B005-89BC6B9A7C3BQ34140931-AA116B48-59F4-4A1B-87AB-A4D7B7612346Q34268855-AF3E9C6C-7996-4ED6-BF49-ADFFF6746A1FQ35127300-1B935A1A-36FB-4D0A-A276-596654AE72DAQ35913925-9E0419CE-0B56-47DB-B460-459782DA6A0BQ36029158-B4F624D4-DD60-4538-842E-07A58E3FDF8FQ36363922-1069E305-80EA-4A70-A641-308ABE11169CQ36422618-F01AFC42-FECF-4C13-9FE4-A8FDA387F5E1Q37111512-C62FF001-850D-4A74-B2C6-5B8B52CB2407Q37432520-AAD0AED5-547F-4E2E-B67A-52717B5F079EQ38524373-A55F29DC-D3EF-4D0D-82B2-D1C91041413FQ38853701-BDE47AA1-F2B2-4074-9CA5-F2A80920DDD7Q39076394-46A2B8E0-F603-4275-918F-EF3DC43762E4Q40216493-1308DDFE-18EB-4B06-BD31-93C07BA1753AQ41040045-37F13E13-7CCD-4943-8C84-3CE58E82053BQ41133863-71AD185E-A518-4ADE-962D-F60FCDA67571Q41579136-EF72AEF4-1B8F-40CD-8DB8-7E0276BFFB2CQ42275949-9FE97E75-8E70-4EFA-B0AD-D4FF73287543Q42571145-16F42E29-A325-43A8-A93B-CE57DA2EE5C7Q47115678-EBD995C7-B75E-4B55-AAF7-71513D59E0D5Q50422323-055EB315-82EE-4BBD-BAAF-4BC68B8726FBQ57295430-890B59F0-2802-4F80-B7CE-E8A3C7B0E9A3
P2860
Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Isolation and characterization ...... umovirus in vitro and in vivo.
@en
Isolation and characterization ...... umovirus in vitro and in vivo.
@nl
type
label
Isolation and characterization ...... umovirus in vitro and in vivo.
@en
Isolation and characterization ...... umovirus in vitro and in vivo.
@nl
prefLabel
Isolation and characterization ...... umovirus in vitro and in vivo.
@en
Isolation and characterization ...... umovirus in vitro and in vivo.
@nl
P2093
P2860
P356
P1433
P1476
Isolation and characterization ...... umovirus in vitro and in vivo.
@en
P2093
Arnita S Barnes
David S Pfarr
Jeffrey M Riggs
Jennifer L Reed
JoAnn A Suzich
Kannaki Senthil
Karyn Folliot
Kathy Coelingh
P2860
P304
P356
10.1128/JVI.00318-06
P407
P577
2006-08-01T00:00:00Z